1. Taiwan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Meribank Biotech Co Ltd

Meribank Biotech Co Ltd

TTPEX:4724
8.72
TWD
-0.37
(-4.07%)
969.36MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.15
3.04
3.65
2.67
2.85
3.73
4.61
5.17
- -
Basic EPS, GAAP
-0.18
-1.13
-1.02
-1.63
-1.62
-1.99
-1.19
-0.89
- -
Free Cash Flow per Basic Share
-0.09
-0.19
-0.47
-0.5
-0.72
-0.58
-4.81
0.93
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7.76
6.86
6.04
9.26
7.44
9.32
13.7
13.02
12.27
Tangible Book Value per Share
7.72
6.82
6.01
9.24
7.28
8.83
3.86
4.38
3.84
Basic Weighted Avg Shares
52
53
53
61
63
63
80
91
94
Sales/Revenue/Turnover
217
161
194
163
180
234
366
472
- -
Operating Margin (%)
-2.14
-35.65
-33.93
-56.38
-61.28
-50.57
-23.65
-10.03
- -
Depreciation Expense
12
21
24
29
32
37
84
155
- -
Net Income, GAAP
-9
-60
-54
-99
-102
-125
-95
-81
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4.3
-37.22
-28.01
-60.83
-56.7
-53.49
-25.85
-17.27
- -
Working Capital
271
230
157
363
284
443
161
223
176
LT Debt
- -
19
50
35
24
15
865
993
940
Total Equity
492
434
383
586
474
671
1,217
1,260
1,188
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-12.94
-13.33
-20.48
-19.32
-22.13
-10.14
-6.64
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
115
134
145
LT Borrowings
159
155
152
LT Finance Leases
862
838
788
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
1,656
1,569
969

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
356
471
426
Cash, Cash Equivalents & STI
136
229
191
Accounts Receivable, Net
172
193
191
Inventories
10
6
6
Total Current Liabilities
225
248
250
Payables & Accruals
- -
- -
- -
ST Debt
115
134
145
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
32.11%
3.51%
Free Cash Flow
- -
175.74%
-122.12%
Net Income, GAAP
- -
13.88%
-13.99%
Sales/Revenue/Turnover
- -
21.91%
28.75%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
366
2025
- -
- -
472
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.19
2025
- -
- -
-0.89
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chien Fang Tsai
Full Time Employees
142
Sector
Health services
Industry
Medical/Nursing services
Address
No.68, Neihu Road Taipei TP Taiwan 11493
IPO Date
Jun 16, 2023
Website
meribank.com.tw
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Meribank Biotech Co., Ltd (4724.TWO) researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan; provides handling, testing, frozen storage, and cryopreservation services for umbilical cord blood hematopoietic stem cells, placental umbilical cord mesenchymal stem cells, peripheral blood stem cells, and immune cells; offers prenatal testing, maternal and child health testing, cell viability testing, and stem cell transplantation applications; develops allogeneic umbilical cord mesenchymal stem cell drugs such as UMC119-06-05 for chronic obstructive pulmonary disease, pre-frailty, and frailty in elderly patients, as well as exosome-based products with INCI certification for cosmetics; and operates in the biotechnology sector targeting healthcare providers, hospitals, research institutions, and families for regenerative medicine and cell therapy. Founded in 2013 and headquartered at No. 68, Section 1, Neihu Road, Taipei City, Taiwan, the company employs 142 people and conducts operations primarily in Taiwan with international certifications including U.S. FDA CMC compliance for its production facility. Recent developments include approval from Taiwan's Ministry of Health and Welfare for Phase I/II clinical trials of its stem cell drug UMC119-06-05 in 2025; launch of self-developed exosomes achieving INCI certification; expansion into the health check market through a partnership with Meilien Health Joint Clinic; entry into medical aesthetics via the EX-MU brand targeting clinics with exosome products; and a NT$647 million acquisition of 99% of Yutuo Management Consulting (Zhubei Yutuo) via stock swap to integrate upstream and downstream maternal-infant services, alongside growth in its management consulting department contributing NT$88.24 million in 2024 sales.